# A Study of LY2127399 in Rheumatoid Arthritis

> **NCT01576549** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 2 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** LY2127399

## Key facts

- **NCT ID:** NCT01576549
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-05
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Insufficient efficacy observed in study BCDM(NCT01198002) and BCDV(NCT01202773).
- **Last updated:** 2018-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01576549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01576549, "A Study of LY2127399 in Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01576549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*